glp 1 receptor agonist New GLP-1 Guidelines for Type 2 Diabetes in 2025 GLP-1 Receptor Agonists and Other
Description
GLP-1 drugs for heart health Trulicity (dulaglutide) was approved in 2020 for individuals with type 2 diabetes, with or without a history of heart disease, to help reduce the risk of serious cardiovascular events, like heart attacks
Despite its overall favorable safety profile, certain adverse reaction risks warrant attention
Efficacy and Safety of Efpeglenatide in Patients with Type 2 Diabetes and Obesity: a Systematic Review
The first time a clinical outcome was recorded within the above time frame was counted in the analysis
and (4) establishment of sophisticated pharmacovigilance networks incorporating artificial intelligence algorithms to optimize therapeutic decision-making processes
